Ampicillin And Sulbactam

Introduction Overview

Generic Name

ampicillin and sulbactam

Brand Name

Unasyn

Dosage Form

Injectable solution for intravenous and intramuscular administration

Drug Class

Penicillins / beta-lactamase inhibitors

Pharmacokinetics

Absorption:
Unasyn, administered as a combination of ampicillin and sulbactam, is not absorbed via the gastrointestinal tract and thus is not given orally. Instead, it is delivered parenterally through intramuscular or intravenous injection. Following intramuscular administration, ampicillin and sulbactam are absorbed into systemic circulation relatively rapidly, achieving therapeutic plasma concentrations. The absorption profile is influenced by blood flow to the injection site and the physiochemical properties of the beta-lactam antibiotic and inhibitor combination.

Distribution:
Once absorbed into systemic circulation, both ampicillin and sulbactam distribute widely throughout body tissues and fluids. The volume of distribution for ampicillin is approximately 0.2 to 0.3 L/kg. Both agents cross inflamed meninges to some extent, achieving therapeutic concentrations in cerebrospinal fluid during meningeal inflammation. Plasma protein binding for ampicillin is about 15-20%, while sulbactam’s binding is similarly low, allowing for good tissue penetration. Distribution is influenced by factors such as blood flow, tissue permeability, and the presence of infection which can increase tissue permeability.

Metabolism:
Ampicillin undergoes minimal hepatic metabolism; the majority of the drug remains unmetabolized. Similarly, sulbactam is also minimally metabolized, predominantly retaining its parent compound form in systemic circulation. The lack of substantial metabolism implies that hepatic impairment may have limited effect on pharmacokinetics, although clinical caution is advisable. Both substances exhibit stability against beta-lactamase enzymes due to sulbactam's inhibitory properties, enhancing the overall efficacy of the combination.

Elimination:
Unasyn components are primarily eliminated renally through glomerular filtration and tubular secretion. Approximately 75-85% of an administered dose is excreted unchanged in urine within 6-12 hours. The elimination half-life of ampicillin is about 1 hour in healthy adults, and sulbactam’s half-life is slightly shorter but similar. Renal impairment significantly prolongs elimination half-life and increases plasma concentrations, necessitating dosage adjustment in patients with compromised renal function. Biliary excretion is minimal. The elimination pattern underscores the importance of renal function monitoring when administering Unasyn, as accumulation can increase the risk of toxicity.

Dosage Forms

**Available Dosage Forms:**
- Injectable powder for solution for intravenous (IV) or intramuscular (IM) administration.
- Available strengths include combinations such as 1.5 g (1 g ampicillin and 0.5 g sulbactam), 3 g (2 g ampicillin and 1 g sulbactam), and 7.5 g vials for reconstitution.

**Dosages for Adults and Adolescents:**
- The typical adult dosage is 1.5 to 3 grams of Unasyn administered every 6 hours via slow IV infusion or IM injection.
- For severe infections or infections caused by resistant organisms, doses can be increased up to 3 g every 6 hours.
- The usual duration of therapy is 7 to 14 days depending on infection severity and clinical response, with some infections necessitating longer treatment.

**Specific Patient Populations:**
- Renal Impairment: Dosage adjustments are necessary in patients with creatinine clearance below 30 mL/min to avoid drug accumulation and toxicity. Interval extension or dose reduction is recommended based on severity.
- Pediatric Use: Safety and efficacy have been established in children over 3 months, with dosing based on body weight.
- Hepatic Impairment: Although metabolism is minimal, caution is advised due to potential altered pharmacodynamics.
- Pregnancy and Lactation: Unasyn crosses the placenta and is excreted in breast milk; only use if clearly needed and benefits outweigh risks.

**Preparation and Administration:**
- Unasyn must be reconstituted with an appropriate diluent prior to administration and used within the recommended time frame depending on storage conditions (refrigeration or room temperature).
- The reconstituted solution should be inspected visually for particulate matter or discoloration before use.
- IM injections are given slowly into a large muscle to reduce pain and irritation.

Mechanism Of Action

Unasyn combines ampicillin, a broad-spectrum beta-lactam antibiotic, with sulbactam, a beta-lactamase inhibitor, aiming to enhance antibacterial efficacy against beta-lactamase–producing bacteria. Ampicillin exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall. These PBPs catalyze the final stages of peptidoglycan synthesis, an essential component for bacterial cell wall structural integrity. Binding of ampicillin inhibits these enzymes, leading to the interruption of cell wall synthesis, which results in bacterial cell lysis and death, particularly in actively dividing bacterial cells.

Sulbactam, though possessing limited intrinsic antibacterial activity, serves as a potent inhibitor of bacterial beta-lactamase enzymes. These enzymes hydrolyze the beta-lactam ring of ampicillin and other penicillins, conferring resistance to bacteria. By irreversibly binding and inhibiting beta-lactamases, sulbactam protects ampicillin from enzymatic degradation, thereby extending ampicillin's spectrum of activity to include organisms that produce beta-lactamase.

The combination thus offers activity against a broad spectrum of aerobic and anaerobic gram-positive and gram-negative bacteria, including strains resistant to ampicillin alone. Cellular uptake and the ability of the combination to reach its PBPs inside bacteria are critical factors influencing its efficacy. Clinical studies have demonstrated that the presence of sulbactam significantly lowers the minimum inhibitory concentrations (MICs) of ampicillin for beta-lactamase–producing pathogens.

Comparatively, Unasyn's mechanism resembles other penicillin/beta-lactamase inhibitor combinations such as amoxicillin-clavulanate, but sulbactam has distinct inhibitory profiles that can vary in effectiveness against different beta-lactamase types. This distinct mechanism underlines Unasyn’s clinical utility in treating mixed infections involving resistant bacterial populations. Ongoing research continues to explore the evolution of beta-lactamase variants and the ability of sulbactam to inhibit emerging resistant enzymes, which is critical for maintaining the clinical efficacy of Unasyn.

Pharmacological Actions

Bactericidal activity against susceptible bacteria by inhibition of cell wall synthesis.
Beta-lactamase inhibition by sulbactam enhancing the spectrum of ampicillin against resistant organisms.
Effective against a wide range of gram-positive and gram-negative aerobic bacteria.
Active against certain anaerobic bacteria important in mixed infections.
Synergistic effect between ampicillin and sulbactam increases antibacterial potency.
Inhibition of bacterial PBPs leads to lysis and death of dividing bacterial cells.
Protection of ampicillin from enzymatic degradation improves treatment outcomes.
Reduction of resistance emergence by targeting beta-lactamase producing strains.
Intramuscular and intravenous formulations allow for systemic antibacterial therapy.
Rapid onset of action following parenteral administration.
Low protein binding facilitates tissue penetration and effective drug delivery.
Drugs shows time-dependent killing properties; efficacy depends on duration concentrations exceed MIC.
Minimal metabolism preventing formation of active metabolites.
Renal excretion ensures rapid clearance in normal kidney function.
Combination therapy allows treatment of polymicrobial infections.

Therapeutic Or Clinical Uses

Treatment of infections caused by susceptible strains of bacteria including respiratory tract infections.
Management of skin and soft tissue infections.
Therapy of intra-abdominal infections such as peritonitis and appendicitis.
Treatment of gynecologic infections including pelvic inflammatory disease.
Use in bacteremia and sepsis caused by susceptible pathogens.
Treatment of urinary tract infections.
Management of bone and joint infections.
Therapy for deep neck infections.
Use in aspiration pneumonia and other mixed aerobic-anaerobic infections.
Treatment of wound infections following trauma or surgery.
Use as empiric therapy in febrile neutropenic patients.
Treatment of infections caused by beta-lactamase producing organisms resistant to ampicillin alone.
Prophylaxis of infections in high-risk surgical procedures where indicated.
Management of infections in hospitalized patients requiring parenteral therapy.
Treatment of infections unresponsive to other penicillins due to beta-lactamase resistance.

Side Or Adverse Effects

Hypersensitivity reactions including rash, pruritus, and urticaria.
Severe allergic reactions such as anaphylaxis and Stevens-Johnson syndrome.
Gastrointestinal disturbances including diarrhea, nausea, and vomiting.
Clostridium difficile-associated diarrhea and colitis, potentially severe.
Local injection site reactions including pain, swelling, and inflammation.
Oral thrush characterized by white patches in the mouth or throat.
Swollen, black, or hairy tongue as a rare adverse manifestation.
Vaginal itching and discharge indicating secondary fungal infection.
Laboratory abnormalities such as transient elevation of liver enzymes.
Neutropenia or other hematologic changes in prolonged use.
Electrolyte imbalances rarely reported with high-dose therapy.
Seizures reported in cases of overdose or in patients with renal dysfunction.
Serious skin reactions including fever, sore throat, blistering, and peeling.
Jaundice and other signs of liver damage in rare cases.
Potential for superinfection with prolonged or repeated therapy.

Precautions

Obtain thorough allergy history for penicillin and cephalosporin hypersensitivity prior to use.
Use cautiously in patients with a history of liver disease or dysfunction.
Monitor renal function regularly during therapy to avoid accumulation and toxicity.
Adjust dosing in renal impairment to prevent adverse effects.
Avoid use in mononucleosis patients due to high incidence of rash.
Monitor for signs and symptoms of Clostridium difficile–associated diarrhea.
Educate patients regarding the full course of therapy to prevent resistance.
Clinicians should be alert for secondary fungal infections during therapy.
Use with caution in pregnancy and breastfeeding; weigh benefits against potential risks.
Inform patients to report any signs of allergic reactions or severe skin events immediately.
Avoid concomitant use with other nephrotoxic agents when possible.
Advise patients that antibiotic use may interfere with laboratory glucose urine tests.
Ensure proper reconstitution and administration to maintain drug stability and efficacy.
Observe for signs of superinfection, especially with prolonged treatment.
Use sterile technique and proper disposal methods for injections to minimize infection risk.

Warnings

Contraindicated in patients with a history of severe hypersensitivity to penicillins or cephalosporins.
Potential for serious hypersensitivity reactions, including anaphylaxis, may occur even with first dose.
Risk of Clostridium difficile–associated diarrhea which can range from mild diarrhea to fatal colitis.
Use with caution in patients with prior allergic reactions to beta-lactams.
Discontinue immediately if severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis develop.
Hepatotoxicity including hepatitis and cholestatic jaundice has been reported; monitor liver function.
Risk of superinfection with prolonged use; monitor clinical status closely.
Do not use Unasyn in patients who developed liver problems during prior Unasyn therapy.
May cause false positive results in certain urine glucose tests leading to diagnostic confusion.
Seizure risk is increased in overdose and in patients with impaired renal function.
Use caution in patients with mononucleosis due to high risk of rash.
Injection site reactions may occur and should be assessed regularly.
Sudden onset of heart problems such as chest pain and palpitations may require immediate medical evaluation.
Patients developing symptoms of new infections during treatment should be re-evaluated promptly.
Avoid abrupt discontinuation before completion of prescribed course to prevent resistance.

Contraindication

Known hypersensitivity to ampicillin, sulbactam, or any penicillin antibiotics.
History of severe allergic reaction (anaphylaxis) or anaphylactoid reactions to any beta-lactam antibiotic.
Previous experience of liver dysfunction, hepatitis, or jaundice during Unasyn therapy.
Hypersensitivity to cephalosporin antibiotics due to potential cross-reactivity.
Use in viral infections such as common cold or influenza where bacterial infection is not established.
Patients with previous severe cutaneous adverse reactions to any component of Unasyn.
Known allergy to any beta-lactam ring-containing antibiotics.
Patients with a history of antibiotic-associated colitis may require alternative therapy.
Concurrent use with drugs contraindicated due to potential for serious interactions.
Use not recommended in neonates due to excipient content and dosing complexity.
Patients with documented hypersensitivity to sulbactam-containing medications.

Drug Interactions

Allopurinol may increase the risk of skin rash when used concomitantly with Unasyn.
Probenecid decreases renal tubular secretion of ampicillin, increasing plasma concentrations and half-life.
Concurrent use of other nephrotoxic agents may increase risk of renal impairment.
Oral anticoagulants may have altered effects with coadministration; monitor coagulation parameters.
Methotrexate levels and toxicities may be enhanced due to decreased renal clearance.
Concomitant use with other beta-lactam antibiotics can increase risk of hypersensitivity.
Potential interference with certain urine glucose testing leading to false positive results.
Live bacterial vaccines may have reduced efficacy during Unasyn therapy.
Concomitant use with bacteriostatic antibiotics may antagonize the bactericidal effect of Unasyn.
Antacids or proton pump inhibitors do not affect Unasyn as it is parenterally administered.
May reduce effectiveness of oral contraceptives due to alterations in gut flora.
Concurrent use with aminoglycosides requires careful monitoring for nephrotoxicity and neurotoxicity.
Use with valproic acid may decrease its serum concentration, leading to reduced seizure control.
Concurrent administration with chloramphenicol or macrolides may antagonize Unasyn’s effect.
Diuretics such as furosemide may enhance nephrotoxicity when combined with Unasyn.

Preparations Of The Drug

Unasyn is supplied as a sterile dry powder for injection in vials intended for solution prior to use.
Available vial sizes include 1.5 g (1 g ampicillin / 0.5 g sulbactam), 3 g (2 g / 1 g), and 7.5 g for extended infusion uses.
Requires reconstitution with appropriate sterile diluents such as sterile water for injection, sodium chloride injection, or dextrose solutions.
After reconstitution, solutions may be further diluted for intravenous infusion according to clinical guidelines.
Storage of the dry powder should be at controlled room temperature away from moisture and heat.
Reconstituted solutions have specific stability data and should be used within recommended timeframes: typically within 6 hours at room temperature and 24 hours refrigerated depending on diluent.
Formulations are designed for intravenous or intramuscular use only; not for oral administration.
Packaging includes single dose or multiple dose vials as per regulatory approvals and clinical usage.
Instructions for sterile technique and proper disposal of needles and syringes accompany preparation guidance.
Some formulations include stabilizers to maintain pH and drug stability.
Unit dose packaging is designed to minimize contamination and ensure dosing accuracy.
Preparation guides emphasize inspecting solutions for particulate matter and discoloration before administration.
Pharmaceutical companies provide detailed prescribing information and guidelines for safe handling.
Extended infusion protocols use higher concentration vials to facilitate prolonged administration.
Patient assistance programs and generic versions are available to improve access.